"Smart teams will do amazing things, but truly diverse teams will do impossible things"
~ Claudia Brind Woody
About Us

Who We Are ?

We are a group of experts experienced in health economics and outcomes research, market access, clinical research and medical communications.
Our team of researchers provide evidence solutions from a range of perspectives thereby, delivering a robust, customized, engaging and reliable solutions to our clients.

Why Choose Us ?

    • Subject area experts, each with 8+ years of experience in pharmaceutical product development, regulatory, HEOR and/or market access strategies.
    • Vast experience in working across multiple therapeutic areas including oncology, metabolic, cardiovascular, respiratory, neurological, auto-immune, renal and gastrointestinal disorders, infectious disease and rare conditions.
    • Customized, cost-effective solutions from a range of perspectives tailored for each project.
    • Achieve tight targets while operating within client’s systems and procedures.
    • Thorough in-house scientific, editorial and quality control review prior to the sponsor review.

  • Rohini Sharma, M.S. (Pharm.) Pharmacology and Toxiclogy, MBA, PhDc

    Valuecom Evidence Based Solutions is managed by Rohini Sharma, a health outcomes expert with more than 14 years of experience in health economics and outcomes research, market access, regulatory writing and clinical research. She has global expertise in health technology assessments and have supported clients with regulatory and reimbursement submissions to agencies in North America, Europe, and Asia-Pacific, in a wide-variety of therapeutic areas.

Our Vision

To be a valued consulting partner to our clients, sharing the common goal of addressing unmet medical needs and making a difference in patient’s lives.

Our Mission

We aspire to collaborate with forward-thinking clients to provide insightful, high-quality and cost-effective services. This will be evident from our wealth of expertise in working across multiple therapeutic areas, our team’s in-depth understanding of the complex drug development process, our passion for our work and our commitment to deliver best-in-class services that support our clientele’s vision.

Publications

Kanters S, Wilkinson L, Vrazic H, Sharma R, et al. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ Open 2019;9:e023458. doi: 10.1136/bmjopen-2018-023458

Sharma R, Wilkinson L, Vrazic H, Popoff E, Lopes S, Kanters S and Druyts E. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018;1-9. doi: 10.1080/03007995.2018.1476332.

Yan K, Balijepalli C, Sharma R, Barakat S, Sun SX, Falcao S, Druyts E, and FitzGerald JM. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019; https://doi.org/10.2217/imt-2019-0113

Sharma R, Koruth RM, Kanters S, Druyts E and Tarhini A. Comparative efficacy and safety of dabrafenib plus trametinib versus competing adjuvant therapies for high-risk melanoma. . Journal of Comparative Effectiveness Research. 2019; https://doi.org/10.2217/cer-2019-0061; ahead of print.

Sharma R, Kaundal RK, Sharma SS. Targeting inflammation by PPAR-gamma agonist in LPS induced pulmonary dysfunction. Indian Journal of Pharmacology 2008; 40(2):S151 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086159/

Sharma R and Sharma SS. Targeting Inflammation in COPD – Hope or Hype. Current Research & Information on Pharmaceutical Sciences 2008;9 (2):22-26 http://www.niper.nic.in/targetting.pdf

Sharma R, Kumar A, Sharma SS. Respiratory Safety Pharmacology. Current Research & Information on Pharmaceutical Sciences. 2007;8 (1):13-16

Koruth R, Sharma R, Kanters S and Druyts E. Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. (2019), SMR Congress 2018 Abstracts. Pigment Cell Melanoma Res, 32:129.

Koruth R, Sharma R, Kanters S and Druyts E. Dabrafenib and trametinib combination versus other interventions for advanced cutaneous melanoma: a network meta-analysis. (2019), SMR Congress 2018 Abstracts. Pigment Cell Melanoma Res, 32:126.

Sharma R, Cheung A, Bolzani A, Barakat S, Sun SX, Druyts E and FitzGerald JM. Comparative efficacy of reslizumab and mepolizumab for the treatment of asthma: A network meta-analysis. Value in Health 2016; 19 (7):A549

Sharma R, Arora M, Ubhadiya B. Impact of placebo run-in period on relative treatment effect in Generalized Anxiety Disorder (GAD). Value in Health 2010; 13 (7):A459 http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2010.00791_2.x/pdf

Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARγ agonist in LPS exposed guinea pigs. Pulmonary Pharmacology and Therapeutics 2009;22:183–189 .http://www.sciencedirect.com/science/article/pii/S1094553908001314

Subscribe
Subscribe